

The Role of Pharmaceuticals in Curing Diseases and Enhancing Health Outcomes

Damos Tami*

Department of Pharmacy, University of New England, Armidale, Australia

DESCRIPTION

Drug distribution is a multifaceted and contentious issue that encompasses a wide range of actors, motivations, and consequences. This study aims to delve into the complexities of drug distribution, exploring the various aspects that contribute to its persistence and the challenges it poses to society. From the illicit drug trade to the pharmaceutical industry, this commentary will provide a comprehensive analysis of drug distribution in all its forms. One of the most visible and concerning aspects of drug distribution is the illicit drug trade [1]. This underground economy operates outside the boundaries of legal frameworks, fuelling addiction, crime, and violence. Organized criminal networks play a significant role in facilitating the transportation and sale of illegal drugs across borders, often exploiting vulnerable populations and perpetuating cycles of poverty and social instability [2]. The illicit drug trade is a global issue, affecting countries and communities around the world. Its impact is felt not only in terms of public health but also in terms of economic costs and strain on law enforcement agencies. Efforts to combat the illicit drug trade have been ongoing for decades, with varying degrees of success.

Strategies range from interdiction and enforcement to demand reduction and harm reduction initiatives, emphasizing the need for a multi-pronged approach to address the root causes and consequences of drug distribution [3]. While the illicit drug trade garners significant attention, it is essential to recognize that drug distribution also encompasses the legal and regulated pharmaceutical industry. Pharmaceutical companies develop, produce, and distribute medications that play a crucial role in treating illnesses and improving health outcomes. However, the pharmaceutical industry is not immune to its own set of challenges and controversies [4]. One pressing concern is the issue of drug pricing and accessibility. The high cost of prescription drugs can create barriers to access, particularly for vulnerable populations without adequate insurance coverage or financial means. This has sparked debates about the ethics of profit-making within the pharmaceutical industry and the need for more affordable alternatives to ensure equitable distribution

of essential medications [5]. Moreover, the distribution of pharmaceutical drugs also raises concerns about overprescribing, off-label use, and the potential for misuse or abuse.

The opioid crisis in the United States serves as a tragic example of how the distribution of prescription painkillers can lead to widespread addiction and devastating consequences for individuals and communities [6]. Beyond the realm of illegal drugs and the pharmaceutical industry, another crucial aspect of drug distribution revolves around the disparities in access to medications and healthcare across different regions of the world. Many developing countries struggle to provide their populations with essential medications, leading to inadequate treatment for prevalent diseases and public health crises [7].

These disparities are often rooted in socioeconomic factors, lack of infrastructure, and insufficient healthcare systems [8,9]. Limited access to medications can result in unnecessary suffering, increased morbidity and mortality rates, and exacerbation of existing inequalities. Addressing these disparities requires collaborative efforts between governments, international organizations, and pharmaceutical companies to ensure fair and equitable distribution of medications globally. In recent years, advancements in technology have significantly impacted drug distribution. The rise of online marketplaces and the dark web has facilitated the trade of illicit drugs, enabling anonymous transactions and making law enforcement efforts more challenging. Cryptocurrencies and encryption techniques further complicate efforts to track and disrupt these activities [10].

CONCLUSION

However, technology also offers potential solutions to some of the challenges associated with drug distribution. Blockchain technology, for instance, holds promise in enhancing the transparency and traceability of pharmaceutical supply chains, reducing the risk of counterfeit drugs and improving overall drug safety. Moreover, telemedicine and remote healthcare services can bridge gaps in access to medications and medical expertise, particularly in remote and underserved areas. Drug distribution is a complex issue that extends beyond the boundaries of legality.

Correspondence to: Damos Tami, Department of Pharmacy, University of New England, Armidale, Australia, E-mail: tami23damos@01.au

Received: 17-Mar-2023, Manuscript No. JAP-23-24229; **Editor assigned:** 22-Mar-2023, PreQC No. JAP-23-24229 (PQ); **Reviewed:** 05-Apr-2023, QC No. JAP-23-24229; **Revised:** 12-Apr-2023, Manuscript No. JAP-23-24229 (R); **Published:** 19-Apr-2023, DOI: 10.35248/1920-4159.23.15.358

Citation: Tami D (2023) The Role of Pharmaceuticals in Curing Diseases and Enhancing Health Outcomes. J Appl Pharm. 15:358.

Copyright: © 2023 Tami D. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

REFERENCES

1. Romero R, Yeo L, Miranda J, Hassan SS, Conde-Agudelo A, Chaiworapongsa T. A blueprint for the prevention of preterm birth: vaginal progesterone in women with a short cervix. *J Perinat Med.* 2013; 41(1):27-44.
2. Stupin JH, David M, Siedentopf JP, Dudenhausen JW. Emergency cerclage versus bed rest for amniotic sac prolapse before 27 gestational weeks: a retrospective, comparative study of 161 women. *Eur J Obstet Gynecol Reprod Biol.* 2008;139(1): 32-37.
3. Ortoft G, Henriksen TB, Hansen ES, Petersen LK. After conisation of the cervix, the perinatal mortality as a result of preterm delivery increases in subsequent pregnancy. *Int J Obstet Gynaecol.* 2010;117(3):258-267.
4. Mousavi SM, Hashemi SA, Ghasemi Y, Atapour A, Amani AM, Savar Dashtaki A, et al. Green synthesis of silver nanoparticles toward bio and medical applications: Review study. *Artif Cells Nan Biotech.* 2018;46(3): S855-S872.
5. Gurunathan S, Kalishwaralal K, Vaidyanathan R, Venkataraman D, Pandian SR, Muniyandi J, et al. Biosynthesis, purification and characterization of silver nanoparticles using *Escherichia coli*. *Colloids Surf. B: Biointerfaces.* 2009;74(1):328-835.
6. Kalimuthu K, Babu RS, Venkataraman D, Bilal M, Gurunathan S. Biosynthesis of silver nanocrystals by *Bacillus licheniformis*. *Colloids and Surfaces B: Biointerfaces* 2008;65(1):150-153.
7. Bagherzade G, Tavakoli MM, Namaei MH. Green synthesis of silver nanoparticles using aqueous extract of saffron (*Crocus sativus L.*) wastages and its antibacterial activity against six bacteria. *Asian Pacific J Trop Biomed.* 2017;7(3):227-33.
8. Tagad CK, Dugasani SR, Aiyer R, Park S, Kulkarni A, Sabharwal S. Green synthesis of silver nanoparticles and their application for the development of optical fiber based hydrogen peroxide sensor. *Bio Chem.* 2013;183:144-9.
9. Zuas O, Hamim N, Sampora Y. Bio-synthesis of silver nanoparticles using water extract of myrmecodia pendan (Sarang Semut plant). *Mat Let.* 2014;123:156-9.
10. Tanwar H, Sachdeva R. Transdermal drug delivery system: A review. *Int J Pharm Sci.* 2016;7(6):2274-2290.